News
Biotech stock jumps as NHS trust rolls out ovarian cancer test
GENinCode shares rose 6 per cent on Thursday after University College London Hospitals (UCLH) became the first NHS trust to introduce its ovarian cancer test.
The AIM-listed company’s stock rose 0.25p to 4.55p after UCLH confirmed it will roll out the Risk of Ovarian Cancer Algorithm (ROCA).
UCLH is offering the service through its Familial Cancer Clinic, in partnership with the North Central London Cancer Alliance.
The test is aimed at women who carry BRCA1 or BRCA2 gene changes.
These inherited mutations raise cancer risk: BRCA1 gives a 44 per cent lifetime chance of ovarian cancer by age 80, while BRCA2 carries a 17 per cent risk.
Preventive surgery to remove fallopian tubes and ovaries is still the most reliable safeguard, but updated guidance from the National Institute for Health and Care Excellence (NICE) supports monitoring for women delaying surgery to preserve fertility or avoid early menopause.
ROCA combines regular blood tests with clinical data to estimate risk.
The system analyses biomarker patterns to improve the likelihood of finding cancer at an earlier stage, when treatment is more effective.
Trials suggest the approach cuts late-stage diagnoses by 44 per cent and could help the NHS save money by detecting cases sooner.
Matthew Walls, chief executive of GENinCode, said the launch was a “significant milestone” and that the firm aims to extend ROCA to other NHS trusts.
Broker Cavendish values the shares at 20p.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Fertility2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Wellness3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Menopause2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






